Novel target PARP9 protein as well as targeting small-molecule compound isoliquiritin thereof and application of novel target PARP9 protein and targeting small-molecule compound isoliquiritin
By developing a small molecule compound isoligerin targeting PARP9, it inhibits the IFNα signaling pathway in dendritic cells, solving the side effects of existing SLE treatment methods, providing a safe and efficient new target, significantly improving SLE symptom.
Patent Information
- Application Number
- CN202411003835.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-25
- Publication Date
- 2024-11-08
AI Technical Summary
The existing SLE treatment methods mainly rely on glucocorticoids and cytotoxic drugs, with serious side effects such as opportunistic infection, osteoporosis and gonad inhibition, and require long-term or lifetime use, and lack safe and effective target treatment plans.
Develop a small molecule compound isoligerin targeting polyadenylase diphosphate polymerase 9 (PARP9), which blocks the IFNα signaling pathway by inhibiting the expression and activation of PARP9 protein in dendritic cells, thereby treating systemic lupus erythematosus .
Effectively reduces PARP9 protein expression and IFNα production, significantly improves SLE symptoms, provides a safe and efficient new target, broadens SLE drug development ideas, and provides a small molecule compound selection with excellent activity.
Smart Images

Figure CN118910231A_ABST
Abstract
Description
Technical Field
[0001] The patent of this invention relates to the field of biomedicine technology, specifically, to the application of a novel target PARP9 and its targeted small molecule compound isoliquiritigenin in the preparation of systemic lupus erythematosus drugs. Background Art
[0002] Systemic lupus erythematosus (SLE) is a typical and common systemic autoimmune disease, characterized by multi-system involvement and the presence of a large number of autoantibodies. SLE mainly affects women, with various forms of disease, involving multiple systems of the body, and some are accompanied by serious organ complications and even death. However, the current treatment measures for SLE are still mainly glucocorticoids and cytotoxic drugs. Current clinical treatment methods have serious side effects such as opportunistic infections, osteoporosis, and gonadal suppression, and are expensive and require long-term or even lifelong use. Therefore, discovering better therapeutic targets and finding a safer and more effective drug for the treatment of SLE has important social and clinical significance.
[0003] The interferon (IFN) system is overactivated, and the expression of IFN-stimulated genes in the blood and tissues of SLE patients increases, that is, the "IFN expression feature" is the hallmark feature of SLE. The abnormal increase in type I interferon (IFN-I), especially the significant increase in IFNα, promotes the occurrence and development of SLE by regulating the survival, activation and function of immune system-related cells. IFNα can be produced by a variety of cells, among which dendritic cells (DC) are the cells that produce the most IFNα. In addition, DC, as the most powerful antigen-presenting cell, is the key cell type that causes immune disorders in SLE. Although IFNα has long been used as a target for the treatment of SLE for related drug development, almost all of them work by directly antagonizing IFNα and blocking its downstream signals. There are currently no reports on the development of drugs targeting the "source" of IFNα production.
[0004] Poly(ADP-ribose)polymerase 9 (PARP9) is an important member of the PARPs protease family. Studies have shown that PARP9 is one of the important molecules in the interferon signal transduction pathway: in vitro experiments have found that after exogenous IFNα stimulation, the expression level of PARP9 in DC cells increased significantly, and PARP9 can promote DC to produce more IFNα through positive feedback regulation. Some studies have pointed out that the DNA methylation level of PARP9 in the peripheral blood of SLE patients, especially those with active SLE, is reduced, suggesting that PARP9 can be used as a predictive indicator for the risk of SLE. However, there are currently no relevant research reports on the specific role of PARP9 in SLE and its relationship with the IFNα signaling pathway.
[0005] To this end, the present invention aims to provide a novel target PARP9 and its targeted small molecule compound isoliquiritigenin and application to solve the above problems. Summary of the invention
[0006] The purpose of the present invention is to solve the technical problems raised in the above background, and provide a new target PARP9 and its targeted small molecule compound isoliquiritin and application. The small molecule compound isoliquiritin (ILQ) capable of regulating the target provided by the present invention has a simple structure, high safety, and obvious effect in treating systemic lupus erythematosus.
[0007] The above object of the present invention is achieved through the following solutions:
[0008] The present invention provides a target PARP9 protein for regulating the IFNα signaling pathway of DC cells.
[0009] The present invention also provides the use of PARP9 protein in preparing medicines, foods or health products for treating systemic lupus erythematosus.
[0010] Furthermore, the medicine, food or health product includes a drug that uses PARP9 protein as a target and inhibits the activation of the IFNα signaling pathway of DC cells.
[0011] Furthermore, the dosage form of the medicine, food or health product is a solid preparation or a liquid preparation.
[0012] Furthermore, the solid preparation is a tablet, capsule, granule, pill, pellet, mixture or powder; the liquid preparation is an injection, oral liquid, soft capsule or aerosol.
[0013] The present invention also provides the use of PARP9 protein in screening drugs for treating systemic lupus erythematosus. The screening method is: using PARP9 protein in DC cells as a target, screening out drugs that specifically inhibit PARP9 protein in DC cells, thereby inhibiting the activation of IFNα signaling pathway mediated by PARP9 in DC cells.
[0014] The present invention also provides a small molecule compound isoliquiritigenin for regulating the PARP9 protein target. The small molecule compound isoliquiritigenin is a natural small molecule compound targeting the PARP9 protein.
[0015] The present invention also provides the use of the small molecule compound isoliquiritigenin in the preparation of medicines, foods or health products for treating systemic lupus erythematosus.
[0016] Furthermore, the active ingredient of the medicine, food or health product includes ILQ or its pharmaceutically acceptable salt, solvate, hydrate or prodrug having the following structure:
[0017]
[0018] Furthermore, after being administered, the drug has at least one of the following functions:
[0019] A. Inhibit the expression of PARP9 protein in DC cells;
[0020] B. Inhibit PARP9-mediated IFNα signaling pathway activation in DC cells.
[0021] The difficulty and significance of the technical problem solved by the present invention are:
[0022] At present, the clinical treatment of SLE is still mainly based on glucocorticoids and cytotoxic drugs. In addition, the current clinical treatment methods have serious side effects such as opportunistic infections, fractures, gonadal suppression, etc., and are expensive and require long-term or even lifelong use. Therefore, it is of great social and clinical significance to find a better therapeutic target and thereby find a safer and more effective SLE treatment drug. The present invention provides a novel target PARP9 and its targeted small molecule compound isoliquiritin and its application. The present invention provides a small molecule compound isoliquiritin (ILQ) that can regulate the target. The compound has a simple structure, high safety, and obvious effect in treating systemic lupus erythematosus.
[0023] Compared with the prior art, the present invention has the following beneficial effects:
[0024] 1. The present invention first discovered that PARP9 protein in DC cells of SLE patients is involved in mediating the activation of IFNα signaling pathway, and the natural small molecule compound ILQ can inhibit the expression and activation of PARP9 protein, thereby inhibiting the activation of IFNα signaling pathway mediated by PARP9, thereby reducing the expression of PARP9 protein and the production of IFNα, and exerting a therapeutic effect on systemic lupus erythematosus;
[0025] 2. The present invention broadens the target of systemic lupus erythematosus drugs, providing a new idea for the drug development of systemic lupus erythematosus; it also provides active small molecule compounds with excellent activity and clear targets, providing a new drug option for the development of products for the treatment of systemic lupus erythematosus. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1 The PARP9 mRNA expression level in peripheral blood PBMC of SLE patients is significantly increased and closely related to the disease activity; HC in the figure is the healthy volunteer control group, SLE is the systemic lupus erythematosus patient group, PBMC is peripheral blood mononuclear cell, SLEDAI-2K is the systemic lupus erythematosus clinical activity score;
[0027] Figure 2 The expression of PARP9 protein level in PBMC and pDC of SLE patients is significantly increased; in the figure, pDC is peripheral plasmacytoid dendritic cell;
[0028] Figure 3 The PARP9 mRNA expression level in PBMCs of SLE patients was positively correlated with disease activity;
[0029] Figure 4 The PARP9 mRNA expression level in pDCs of SLE patients was positively correlated with the plasma IFNα level;
[0030] Figure 5 The expression of PARP9 in pDCs of SLE patients was increased, accompanied by increased activation of downstream PI3Kp85α signaling.
[0031] Figure 6 It was discovered through high-throughput screening technology that ILQ can specifically bind to PARP9;
[0032] Figure 7 ILQ can reduce the expression of PARP9 in BMDCs and inhibit the activation of IFNα signaling pathway mediated by PARP9. Figure 7 AB), and had no significant effect on the survival of BMDCs ( Figure 7 C), indicating that ILQ has no obvious drug toxicity to cells;
[0033] Figure 8ILQ can significantly reduce the urine protein level of MRL / lpr mice (SLE model mice) and alleviate the renal tissue damage of SLE model mice;
[0034] In the figure, MRL / lpj: n=6, MRL / lpr+NS: n=6, MRL / lpr+DMSO: n=4, MRL / lpr+ILQ: n=4; *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. DETAILED DESCRIPTION
[0035] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention.
[0036] The present invention is described in detail and specifically by specific examples and accompanying drawings below to provide a better understanding of the present invention, but the following examples do not limit the scope of the present invention. The methods in the examples are conventional methods unless otherwise specified, and the reagents used are conventional commercial reagents or reagents prepared according to conventional methods unless otherwise specified.
[0037] Example 1: In vitro experiments
[0038] The embodiments of the present invention provide a target PARP9 protein for regulating the IFNα signaling pathway of DC cells in systemic lupus erythematosus and the use of the PARP9 protein in the preparation of a drug, food or health product for treating systemic lupus erythematosus.
[0039] In this embodiment, the drug, food or health product includes a drug that uses PARP9 protein as a target and inhibits the activation of the DC cell IFNα signaling pathway. The drug, food or health product is in the form of a solid preparation or a liquid preparation. The solid preparation is a tablet, capsule, granule, pill, drop pill, mixture or powder; the liquid preparation is an injection, oral liquid, soft capsule, or aerosol.
[0040] The embodiment of the present invention also provides the use of PARP9 protein in screening drugs for treating systemic lupus erythematosus. The screening method is: using PARP9 protein as a target, screening drugs that inhibit the activation of IFNα signaling pathway of DC cells.
[0041] The present invention also provides a small molecule compound isoliquiritigenin for regulating the PARP9 protein target. The small molecule compound isoliquiritigenin is a natural small molecule compound targeting the PARP9 protein.
[0042] The present invention also provides the use of the small molecule compound isoliquiritigenin in the preparation of a medicine, food or health product for treating systemic lupus erythematosus. The active ingredient of the medicine, food or health product includes ILQ or its pharmaceutically acceptable salt, solvate, hydrate or prodrug having the following structure:
[0043]
[0044] After being administered, the above-mentioned drug in the embodiment of the present invention has at least one of the following functions:
[0045] A. Inhibit the expression of PARP9 protein in DC cells;
[0046] B. Inhibit PARP9-mediated IFNα signaling pathway activation in DC cells.
[0047] The steps used in this part of the experiment are as follows: Step 1: Ficoll density gradient centrifugation was used to separate HC and SLE peripheral blood PBMCs. Some samples were further separated by immunomagnetic bead sorting technology to obtain HC and SLE peripheral blood pDCs. Real-time fluorescence quantitative PCR (Real-time qPCR) and protein immunoblot were used to detect PARP9 in PBMCs and pDCs. mRNA expression and protein expression levels, and use clinical data to analyze the correlation between PARP9 and clinical indicators; Step 2: Use Western blot to detect the expression level of PARP9 and the expression and activation of the IFNα signaling pathway (PI3K-AKT3-IRF3) in pDC; Step 3: High-throughput virtual screening of small molecule compounds that can bind to PARP9 based on molecular docking technology; Step 4: Obtain and culture mouse bone marrow-derived dendritic cells (BMDC), perform in vitro drug treatment according to the drugs screened in Step 3, and use Western blot to determine the expression of PARP9 and its downstream PI3K-AKT3-IRF3 signaling pathway after ILQ treatment; Step 5: Use CCK-8 to detect whether ILQ has drug toxicity to BMDC.
[0048] Example 2: Animal Experiment
[0049] The steps used in this experiment are as follows: Step 1: 8-week-old MRL / lpr mice were selected and divided into a blank group (MRL / lpj, n=6), a normal saline group (MRL / lpr+NS, n=6), a DMSO group (MRL / lpr+DMSO, n=4), and an ILQ group (MRL / lpr+50 mg / kg ILQ, n=4) to establish a lupus mouse model; after 2 weeks of adaptive feeding, the mice were given drug gavage daily at 10 weeks of age, and the mice were raised in the same environment for 8 consecutive weeks.
[0050] Step 2: Starting from 10 weeks of age, the urine protein level of mice was measured once a week using urine protein test strips. Samples were collected at 18 weeks of age for histopathological examination (HE staining) to evaluate the level of renal structural damage in mice.
[0051] In summary, the PARP9 protein in the embodiments of the present invention is a key target protein for regulating the IFNα signaling pathway in DCs of patients with systemic lupus erythematosus, and may be a potential target indicator for evaluating the disease activity of systemic lupus erythematosus; the small molecule compound isoliquiritigenin provided by the present invention can directly target the PARP9 protein, inhibit its expression and activity, and thereby inhibit the activation of the IFNα signaling pathway and alleviate the lupus condition.
[0052] The specific embodiments of the present invention are described in detail above, but they are only examples and the present invention is not limited to the specific embodiments described above. For those skilled in the art, any equivalent modification and substitution of the present invention are also within the scope of the present invention. Therefore, the equalization and modification made without departing from the spirit and scope of the present invention should be included in the scope of the present invention.
Claims
1. A target protein PARP9 that regulates the IFNα signaling pathway in DC cells in SLE.
2. Use of the PARP9 protein according to claim 1 in the preparation of medicines, foods or health products for treating systemic lupus erythematosus.
3. The use according to claim 2, characterized in that The medicine, food or health product includes a medicine which uses PARP9 protein as a target and inhibits the activation of IFNα pathway of DC cells.
4. The use according to claim 3, characterized in that The dosage form of the medicine, food or health product is a solid preparation or a liquid preparation.
5. The use according to claim 4, characterized in that The solid preparation is a tablet, capsule, granule, pill, pellet, mixture or powder; the liquid preparation is an injection, oral liquid, soft capsule or aerosol.
6. The use of the PARP9 protein according to claim 1 in screening drugs for treating systemic lupus erythematosus, characterized in that: The screening method is: using PARP9 protein as a target to screen out drugs that inhibit the activation of the IFNα pathway of DC cells.
7. A small molecule compound isoliquiritigenin for regulating the target as claimed in claim 1, characterized in that: The small molecule compound isoliquiritigenin is a natural small molecule compound targeting PARP9 protein.
8. Use of the small molecule compound isoliquiritigenin as claimed in claim 7 in the preparation of medicines, foods or health products for treating systemic lupus erythematosus.
9. The use according to claim 8, characterized in that The active ingredient of the medicine, food or health product includes ILQ or its pharmaceutically acceptable salt, solvate, hydrate or prodrug having the following structure:
10. The use according to claim 9, characterized in that After being administered, the drug has at least one of the following functions: A. Inhibit the expression of PARP9 protein in DC cells; B. Inhibit PARP9-mediated IFNα signaling pathway activation in DC cells.
Citation Information
Cited By
Application of isoliquiritin in preparation of medicine for preventing and treating central nervous injury caused by mustard gas
CN121370918A
